Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03ING
|
||||
| Former ID |
DIB009299
|
||||
| Drug Name |
Anrukinzumab
|
||||
| Synonyms |
Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Company |
Genentech
|
||||
| CAS Number |
CAS 910649-32-0
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-13 | Target Info | Modulator | ||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | Glucocorticoid receptor regulatory network | ||||
| IL12 signaling mediated by STAT4 | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| References | |||||
| Ref 521957 | ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health. | ||||
| Ref 889341 | ClinicalTrials.gov (NCT00410280) Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma | ||||
| Ref 889361 | ClinicalTrials.gov (NCT01284062) Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.